IPHA - Innate Pharma SA
1.7855
0.076 4.229%
Share volume: 53,726
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.03%
PREVIOUS CLOSE
CHG
CHG%
$1.71
0.08
0.04%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-10.94%
1 Month
-16.99%
3 Months
-6.56%
6 Months
-20.09%
1 Year
-34.23%
2 Year
-46.39%
Key data
Stock price
$1.79
DAY RANGE
$1.74 - $1.87
52 WEEK RANGE
$1.29 - $3.51
52 WEEK CHANGE
-$34.23
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09-11-2025
Company detail
CEO: Mondher Mahjoubi
Region: US
Website: innate-pharma.com
Employees: 220
IPO year: 2019
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: innate-pharma.com
Employees: 220
IPO year: 2019
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Innate Pharma S.A. discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the. treatment of cutaneous T-cell and peripheral T-Cell lymphoma. Its products include Monalizumab, an immune checkpoint inhibitor that is in. Phase III clinical trial to treat colorectal and lung cancer.
Recent news
